Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Oxford Biomedica plc

Capitalization 787M 1.06B 909M 822M 1.44B 97.25B 1.48B 9.68B 3.88B 46.62B 3.97B 3.89B 167B P/E ratio 2025 *
-22.8x
P/E ratio 2026 * -67.4x
Enterprise value 753M 1.01B 870M 787M 1.38B 93.08B 1.42B 9.26B 3.71B 44.62B 3.8B 3.72B 160B EV / Sales 2025 *
4.49x
EV / Sales 2026 * 3.44x
Free-Float
76.07%
Yield 2025 *
-
Yield 2026 * -
1 day-1.69%
1 week-3.02%
Current month-3.61%
1 month-21.68%
3 months-0.30%
6 months+6.51%
Current year+3.58%
1 week 586
Extreme 586
672
1 month 586
Extreme 586
844
Current year 586
Extreme 586
962
1 year 232.5
Extreme 232.5
962
3 years 164.29
Extreme 164.288
962
5 years 164.29
Extreme 164.288
1,678
10 years 148.88
Extreme 148.885
1,678
Manager TitleAgeSince
Chief Executive Officer 64 27/03/2023
Director of Finance/CFO 47 02/09/2024
Chief Operating Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 60 15/03/2018
Chairman 70 24/06/2020
Director/Board Member 75 01/03/2021
Change 5d. change 1-year change 3-years change Capi.($)
-1.69%-3.02%+131.13%+30.96% 1.06B
+0.22%-0.25%+22.52%+96.50% 45.56B
+3.35%+0.43%+51.85%+17.36% 40.81B
+0.06%-2.14%+96.87%+700.06% 31.01B
+5.93%-16.74%-20.37%-34.18% 21.05B
-1.42%+2.27%+49.79%-28.09% 19.37B
-0.88%-1.28%+28.11%-28.98% 17.15B
-0.09%+20.57%+62.75%+189.79% 13.54B
-0.24%+8.07%-9.23%+995.97% 12.66B
-1.79%+16.72%+65.93% - 12.33B
Average +0.36%+2.82%+47.94%+215.49% 21.45B
Weighted average by Cap. +0.96%+0.82%+41.24%+199.13%

Financials

2025 *2026 *
Net sales 168M 226M 194M 175M 306M 20.73B 316M 2.06B 826M 9.94B 847M 829M 35.58B 227M 306M 263M 238M 415M 28.1B 428M 2.8B 1.12B 13.47B 1.15B 1.12B 48.24B
Net income -30.5M -41.03M -35.24M -31.85M -55.7M -3.77B -57.46M -375M -150M -1.81B -154M -151M -6.47B -11M -14.8M -12.71M -11.49M -20.09M -1.36B -20.73M -135M -54.19M -652M -55.56M -54.38M -2.33B
Net Debt -33.76M -45.42M -39M -35.26M -61.65M -4.17B -63.6M -415M -166M -2B -170M -167M -7.16B -3.6M -4.84M -4.15M -3.76M -6.57M -444M -6.77M -44.23M -17.71M -213M -18.16M -17.77M -763M
Logo Oxford Biomedica plc
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.
Employees
900
Date Price Change Volume
12/03/26 640.00 p -1.69% 23,550
10/03/26 651.00 p +5.85% 202,250
09/03/26 615.00 p -1.44% 259,684
06/03/26 624.00 p -2.19% 206,813
05/03/26 638.00 p -3.19% 127,938
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
6.510GBP
Average target price
8.455GBP
Spread / Average Target
+29.88%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW